GAMMA Investing LLC grew its holdings in CVS Health Co. (NYSE:CVS - Free Report) by 20,124.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,264,825 shares of the pharmacy operator's stock after acquiring an additional 1,258,571 shares during the quarter. GAMMA Investing LLC owned 0.10% of CVS Health worth $85,692,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the stock. McIlrath & Eck LLC lifted its stake in shares of CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after purchasing an additional 174 shares during the period. Coppell Advisory Solutions LLC lifted its position in CVS Health by 17.3% in the fourth quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator's stock valued at $56,000 after buying an additional 189 shares during the last quarter. EagleClaw Capital Managment LLC lifted its position in shares of CVS Health by 3.4% during the fourth quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock worth $275,000 after purchasing an additional 200 shares in the last quarter. Manchester Capital Management LLC lifted its position in shares of CVS Health by 4.8% during the fourth quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock worth $200,000 after purchasing an additional 204 shares in the last quarter. Finally, Angeles Investment Advisors LLC lifted its position in shares of CVS Health by 3.7% during the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock worth $256,000 after purchasing an additional 204 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.
CVS Health Stock Down 0.8%
Shares of CVS Health stock traded down $0.52 during trading on Thursday, reaching $63.05. The stock had a trading volume of 6,599,235 shares, compared to its average volume of 11,115,336. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $72.51. The company has a market capitalization of $79.76 billion, a price-to-earnings ratio of 17.23, a P/E/G ratio of 0.98 and a beta of 0.56. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The stock has a fifty day moving average price of $65.30 and a two-hundred day moving average price of $59.84.
CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter in the prior year, the business earned $1.31 earnings per share. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. Sell-side analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.
CVS Health Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.22%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio is currently 63.48%.
Analyst Ratings Changes
Several research firms recently commented on CVS. Wall Street Zen upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Leerink Partnrs raised shares of CVS Health from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 12th. Piper Sandler boosted their target price on shares of CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research note on Friday, March 21st. JPMorgan Chase & Co. lifted their price target on CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a report on Tuesday, February 18th. Finally, Robert W. Baird boosted their target price on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $74.75.
Read Our Latest Stock Report on CVS
CVS Health Company Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Further Reading
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
